Moneycontrol
HomeNewsWorldDeadline looms, but COVID-19 relief deal may be far off
Trending Topics

Deadline looms, but COVID-19 relief deal may be far off

Nancy Pelosi negotiated for nearly an hour on Monday with Trump’s top emissary, Treasury Secretary Steven Mnuchin, and her office said they are continuing to narrow their differences.

October 20, 2020 / 10:15 IST
Story continues below Advertisement

House Speaker Nancy Pelosi reported some progress in advance of a Tuesday deadline for reaching a pre-election deal with President Donald Trump on a new coronavirus relief package, but the same core problems bedeviling the effort remain in place despite optimistic talk from the president and his team.

Pelosi negotiated for nearly an hour on Monday with Trump’s top emissary, Treasury Secretary Steven Mnuchin, and her office said they are continuing to narrow their differences.

Story continues below Advertisement

“Finally, they have come to the table and we’re going to try to get something done,” Pelosi said on MSNBC Monday evening. She said the two sides would take stock on Tuesday, which she has staked out as the deadline if a deal is to be reached before the election.

“Let’s make a judgment. We may not like this, we may not like that but let’s see on balance if we can go forward,” Pelosi said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show